Tablets 80mg/400mg, 160mg/800mg

Oral solution 40mg/200mg/5ml, 80mg/400mg/5ml

 

On advice of Microbiology only.

 

Short-term use where the prescriber has initially requested sensitivities on a sample, and they then receive or request advice from a specialist with the recommendation for prescribing co-trimoxazole.

 

Long-term use - detailed prescribing support information should be provided by the intiating specialist to support long term prescribing and to make monitoring clear. Monitor blood counts on prolonged treatment.

 

No regular routine monitoring will be required in primary care for the first 3 years of treatment. Patient monitoring will be carried out as part of tertiary care services at least monthly for the first year and every 6–12 weeks in year 2 post-transplant. For the limited number of patients still using prophylactic co-trimoxazole after 2 years post-transplant monitoring will be carried out in tertiary care services every 3–4 months in year 3.

Prophylactic co-trimoxazole treatment would not be expected to continue beyond 3 years for most patients. Where patients require prophylactic co-trimoxazole in years 4 and 5 post-transplant, consultants should liaise with primary care clinicians to ensure suitable blood monitoring arrangements are requested.